By Leslie C. Norins, MD, PhD | August, 2017 Alzheimer’s disease (AD) is an expanding health problem. Deaths from it increased 55 percent in 15 years, according to the Centers for Disease Control and Prevention. The affliction breaks hearts of loved ones, and the finances of family, insurance companies, and government. Most everyone knows of a victim. Despite huge research expenditures, we do not yet know the cause. The “Big Two” suspects seen in patient brains, amyloid plaques and protein tangles, have been studied extensively for years, but so far have not led to many useful answers. It’s time to make an exhaustive
Robots are continually in the news for taking over many industrial tasks and causing job losses, but they have not made many inroads into creative fields. Like advertising. Automation of ad production might seem far-fetched, since advertisers customarily require their ads be differentiated from those of their competitors. However
If “Facebook advertising” were a pharmaceutical, its $27 billion annual sales would dwarf those of every other available drug. But it could not be sold in the U.S. until Facebook (FB) provided the FDA with rigorous proof of efficacy?
This year the Post Office’s “Forever” stamps celebrate their tenth birthday. You remember how they work: buy one now, and you can use it “forever” to mail a simple first class letter—no matter how
Could Zika mosquitoes also transmit HIV occasionally? Official theory says “No”, but—surprise-- the most relevant mosquitoes have never been tested
As a forty-year loyal subscriber to the New York Times, I have watched with concern as, in response to the difficult publishing environment, it has announced sequential platoons of staff reductions. Recently, it revealed that an internal committee had recommended
The “Big Three” national print newspapers (Wall Street Journal, New York Times, USA Today) have been battered by declines in circulation and advertising. Pessimism permeates print. The enemy is claimed to be “digital”, but